Investor Presentation

Investment Highlights NASDAQ: CRBP Founded: 2014 Employees: 77 Based in: Norwood, MA Capital raised to-date: $168M Additional awards and grants from NIH and CFF: $45M Upfront payment from Kaken collaboration: $27M Leading ECS Pipeline Rationally-designed small molecules Proven expertise in clinical development of ECS- targeting drug candidates ~$5 billion Potential Annual Market Opportunity¹ 350,000 Patients in Major Markets¹ Unique MOA Target CB1 and CB2 receptors: G-Protein Coupled Receptors (GPCRs) Modulate inflammation + fibrosis w/o immunosuppression Late and Early Stage Programs Lenabasum* Phase 3 for SSC and DM Phase 2 for CF and SLE CRB-4001* Preparing for Phase 1 in 2019 Planned NIH Phase 2 Global Commercial Rights 600+ Drug Candidates Japan: Lenabasum partnered with Kaken Pharmaceutical Co. 4X 1: Health Advances, LLC; Patient population and market value for lenabasum in 3 indications in U.S., EU, Japan; excludes lenabasum for treatment of lupus, CRB-4001 and library of drug candidates; *Lenabasum and CRB-4001 are not currently FDA-approved

View entire presentation